18 March 2026
18 March 2026
The MC2 system enables examinations in the same room as caregivers, reducing the need to separate families during procedures.
START will leverage Trialing’s platform to distribute curated information on ongoing early-phase oncology trials.
During the review process, the FDA provided label drafts in December 2025 and March 2026.
The study will assess the effects of SUL-238 on high energy phosphates using 31P-MRS in PD patients.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
